Navigation Links
Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
Date:9/16/2010

SEATTLE, Sept. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) (the "Company") announced today the results from its Annual Meeting of Shareholders (the "Annual Meeting") held on Thursday, September 16, 2010.

At the Annual Meeting, shareholders elected John H. Bauer and Phillip M. Nudelman, M.D. to serve on the Company's Board of Directors until the Company's 2013 Annual Meeting. Shareholders approved the proposals to (i) amend the Company's amended and restated articles of incorporation to increase the total number of authorized shares and authorized shares of common stock and (ii) amend the Company's 2007 Equity Incentive Plan, as amended (the "Plan"), to increase the number of shares available for issuance under the Plan. Shareholders ratified the selection of Stonefield Josephson, Inc. as the Company's independent auditors for the year ending December 31, 2010.

About Cell Therapeutics, Inc.Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include the risk factors listed or described from time to time in the Company's filings with the U.S. Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, the Company does not intend to update or alter its forward-looking statem
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
3. Cell Therapeutics, Inc. Announces Reverse Stock Split
4. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
6. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
8. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
9. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
10. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... ROCKVILLE, Md. , April 16, 2015 /PRNewswire/ ... "RegeneRx") today announced its U.S. joint venture with ... conduct a phase 3 clinical trial for the ... dose-response, confirmatory trial for dry eye syndrome (DES) ... ReGenTree,s preservative-free eye drops, RGN-259/GBT201, this year.  Each ...
(Date:4/16/2015)... 16, 2015 ChemRar ... investment and R&D group, and Lancet, Russian ... development and commercialization of new medicines in ... intention to stimulate the innovative development of ... (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
(Date:4/16/2015)... April 16, 2015 Avelas Biosciences, an ... cancer surgeries, announced today that it has initiated a ... AVB-620, in women with primary, non-recurrent breast cancer undergoing ... welcomed the addition of Steven Chen , M.D., ... open label, dose escalation study will enroll up to ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... 2011   Elsevier, the leading ... will present awards to outstanding members of the wilderness medicine ... Wilderness Medicine Scientific Conference & Annual Meeting , taking place ... rd . The aim of the Wilderness Medicine ...
... Switzerland and RALEIGH, North Carolina, July 26, 2011 ... a therapeutically focused contract research organisation (CRO) with ... Debiopharm Group™ ("Debiopharm"), a Swiss-based global biopharmaceutical group ... diagnostics, today announced a strategic partnership. Under the ...
... 25, 2011 Rising star Divine Skin Inc. (DSKX), which ... Robin Powell, a long-time leader in the cosmetics industry, to ... of retirement by Divine Skin because I believe their innovative ... give proven results with a ,wow, factor." ...
Cached Biology Technology:Elsevier Collaborates with the Wilderness Medicine Society to Award Outstanding Members 2Elsevier Collaborates with the Wilderness Medicine Society to Award Outstanding Members 3INC Research and Debiopharm Group(TM) Announce Strategic Partnership 2INC Research and Debiopharm Group(TM) Announce Strategic Partnership 3Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX) 2
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... New research from the University of Michigan Comprehensive ... protein that fuels an inflammatory pathway does not turn ... cancer stem cells. This provides a potential target for ... of the disease. The researchers identified a protein, ...
... glioblastoma cancers so difficult to treat is that malignant cells ... fibers and blood vessels to invade new locations. Now, researchers ... the cancer by using a film of nanofibers thinner than ... of invading new areas, the migrating cells latch onto the ...
... life on earth, is also its least explored environment. ... the ocean,s deep regions, exploiting the deep,s resources and ... for the planet at risk. Lisa Levin, a ... San Diego, believes the vital functions provided by the ...
Cached Biology News:New finding points to potential options for attacking stem cells in triple-negative breast cancer 2Researchers hijack cancer migration mechanism to 'move' brain tumors 2Researchers hijack cancer migration mechanism to 'move' brain tumors 3Researchers hijack cancer migration mechanism to 'move' brain tumors 4Scientists call for new stewardship of the deep ocean: Earth's last frontier 2Scientists call for new stewardship of the deep ocean: Earth's last frontier 3
Sprague-Dawley rats, 7-8 weeks old, mixed gender; tissue is collected fresh, frozen on dry ice within minutes of sacrifice and stored at -20C; individual tissue weight approx. 0.05 gram....
Contains L-glutamine...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Biology Products: